<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Glaukos Corporation GKOS, an ophthalmic medical technology 
 company focused on the development and commercialization of breakthrough 
 products and procedures designed to transform the treatment of glaucoma, 
 today announced that an analysis published in the Journal of Medical 
 Economics evaluating various options for treating elevated 
 intraocular pressure (IOP) in open-angle glaucoma patients showed that 
 two iStent® Trabecular Micro-Bypass Stents had a lower projected 
 average cumulative cost at five years than either selective laser 
 trabeculoplasty (SLT) or topical glaucoma medication only.
 
 
 The population-based, annual state-transition, probabilistic, 
 cost-of-care model used in the analysis was designed to assess direct 
 costs for three treatment options – two iStents, SLT or topical 
 medication only – over a five-year time horizon. A clinician panel 
 provided treatment strategy change probabilities and direct costs for 
 drugs, procedures and complications that were included in the analysis.
 
 
 According to the study authors, the projected average cumulative cost at 
 five years was $4,420 for the two-stent procedure, compared to $4,730 
 for SLT and $6,217 for topical medication only. The model showed that 
 while the two-stent procedure had the highest initial year cost, it also 
 had the lowest annual marginal cost for each subsequent year. Over the 
 same time period, costs in each year following SLT or topical medication 
 only were more than double that of the two-stent procedure.
 
 
 "While numerous international studies have shown the ability of two 
 trabecular meshwork stents to effectively control IOP in open-angle 
 glaucoma patients, this analysis is the first to reveal the potential 
 cost efficiency of trabecular stenting, especially over longer time 
 horizons," said John P. Berdahl, MD, a South Dakota-based ophthalmic 
 surgeon and one of the authors of the Journal of Medical Economics 
 article. "Our research indicates that the two-stent treatment option may 
 reduce glaucoma-related health resource use and contribute to direct 
 cost savings, particularly when compared to topical medication only, 
 which is the most commonly used treatment option today but is often 
 ineffective due to high rates of patient non-compliance."
 
 
 Glaukos is the study sponsor and the pioneer of Micro-Invasive Glaucoma 
 Surgery, or MIGS. MIGS involves insertion of a micro-scale device from 
 within the eye's anterior chamber through a small corneal incision. MIGS 
 devices are designed to reduce intraocular pressure by restoring the 
 natural outflow pathways for aqueous humor. In 2012, Glaukos received 
 U.S. Food &amp; Drug Administration (FDA) approval for the iStent, 
 which is implanted in conjunction with cataract surgery and has been 
 shown to lower IOP in adult patients with mild-to moderate open-angle 
 glaucoma.
 
 
 The company also is pursuing FDA approval of two versions of its 
 next-generation iStent inject® Trabecular Micro-Bypass device: one 
 for use in combination with cataract surgery and another for use in a 
 standalone procedure. The iStent inject is designed to deploy two 
 stents into separate trabecular meshwork locations and is being 
 evaluated in FDA clinical trials for IOP reduction. The iStent inject 
 is approved for use in the European Union, Canada, Australia, Singapore 
 and Brazil. The company also is pursuing FDA approval of a third MIGS 
 device, the iStent SUPRA, which accesses the uveoscleral 
 pathway for aqueous humor outflow.
 
 
 "Our core strategy is to provide a full complement of micro-scale 
 treatment options that can effectively manage IOP and overcome many of 
 the drawbacks of conventional therapies," said Thomas Burns, Glaukos 
 president and chief executive officer. "Peer-reviewed study results like 
 these help to illustrate the potential for our technologies to offer 
 important clinical and economic benefits for physicians, patients and 
 the healthcare system."
 
 
 The full Journal of Medical Economics article is available <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F13696998.2017.1327439&amp;esheet=51562780&amp;newsitemid=20170522005299&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=b787ead5bc6defe6f60482cb0b02ae36" rel="nofollow" rel="nofollow">here</a>.
 
 
 Glaucoma is characterized by progressive, irreversible and largely 
 asymptomatic vision loss caused by optic nerve damage. There is no cure 
 for the disease and reducing IOP is the only proven treatment. According 
 to Market Scope, more than 80 million people worldwide have glaucoma, 
 including 4.5 million people in the United States. Open-angle glaucoma 
 is the most common form, affecting approximately 3.6 million people in 
 the United States.
 
 
 About iStent Trabecular Micro-Bypass Stent (U.S.)
 
 
 Indication for Use: The iStent Trabecular Micro-Bypass Stent 
 is indicated for use in conjunction with cataract surgery for the 
 reduction of intraocular pressure (IOP) in adult patients with 
 mild-to-moderate open-angle glaucoma currently treated with ocular 
 hypotensive medication.
 
 
 Contraindications: The iStent is contraindicated in eyes with 
 primary or secondary angle closure glaucoma, including neovascular 
 glaucoma, as well as in patients with retrobulbar tumor, thyroid eye 
 disease, Sturge-Weber Syndrome or any other type of condition that may 
 cause elevated episcleral venous pressure.
 
 
 Warnings: Gonioscopy should be performed prior to surgery to exclude 
 PAS, rubeosis, and other angle abnormalities or conditions that would 
 prohibit adequate visualization of the angle that could lead to improper 
 placement of the stent and pose a hazard. The iStent is 
 MR-Conditional meaning that the device is safe for use in a specified MR 
 environment under specified conditions, please see label for details.
 
 
 Precautions: The surgeon should monitor the patient postoperatively for 
 proper maintenance of intraocular pressure. The safety and effectiveness 
 of the iStent has not been established as an alternative to the 
 primary treatment of glaucoma with medications, in children, in eyes 
 with significant prior trauma, chronic inflammation, or an abnormal 
 anterior segment, in pseudophakic patients with glaucoma, in patients 
 with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in 
 patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg 
 after "washout" of medications, or in patients with prior glaucoma 
 surgery of any type including argon laser trabeculoplasty, for 
 implantation of more than a single stent, after complications during 
 cataract surgery, and when implantation has been without concomitant 
 cataract surgery with IOL implantation for visually significant cataract.
 
 
 Adverse Events: The most common post-operative adverse events reported 
 in the randomized pivotal trial included early post-operative corneal 
 edema (8%), BCVA loss of ≥ 1 line at or after the 3 month visit (7%), 
 posterior capsular opacification (6%), stent obstruction (4%) early 
 post-operative anterior chamber cells (3%), and early post-operative 
 corneal abrasion (3%). Please refer to Directions for Use for additional 
 adverse event information.
 
 
 Caution: Federal law restricts this device to sale by, or on the order 
 of, a physician. Please reference the Directions for Use labeling for a 
 complete list of contraindications, warnings, precautions, and adverse 
 events.
 
 
 About Glaukos
 
 
 Glaukos (<a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glaukos.com&amp;esheet=51562780&amp;newsitemid=20170522005299&amp;lan=en-US&amp;anchor=www.glaukos.com&amp;index=2&amp;md5=1d00f4330d31013aa87ef349fd0f3864" rel="nofollow" rel="nofollow">www.glaukos.com</a>) 
 is an ophthalmic medical technology company focused on the development 
 and commercialization of breakthrough products and procedures designed 
 to transform the treatment of glaucoma, one of the world's leading 
 causes of blindness. The company pioneered Micro-Invasive Glaucoma 
 Surgery, or MIGS, to revolutionize the traditional glaucoma treatment 
 and management paradigm. Glaukos launched the iStent®, 
 its first MIGS device, in the United States in July 2012 and is 
 leveraging its platform technology to build a comprehensive and 
 proprietary portfolio of micro-scale injectable therapies designed to 
 address the complete range of glaucoma disease states and progression. 
 The company believes the iStent, measuring 1.0 mm long and 0.33 
 mm wide, is the smallest medical device ever approved by the FDA.
 
 
 Forward-Looking Statements
 
 
 All statements other than statements of historical facts included in 
 this press release that address activities, events or developments that 
 we expect, believe or anticipate will or may occur in the future are 
 forward-looking statements. Although we believe that we have a 
 reasonable basis for forward-looking statements contained herein, we 
 caution you that they are based on current expectations about future 
 events affecting us and are subject to risks, uncertainties and factors 
 relating to our operations and business environment, all of which are 
 difficult to predict and many of which are beyond our control, that may 
 cause our actual results to differ materially from those expressed or 
 implied by forward-looking statements in this press release. These 
 potential risks and uncertainties include, without limitations, the 
 continued efficacy and cost efficiency of our products as might be 
 suggested in the study described herein; the extent to which the company 
 will be able to obtain regulatory approval for its next-generation 
 products; and the extent to which the company's next-generation products 
 will obtain an indication of use for multiple stents and multiple 
 pathways for aqueous fluid outflow. These risks, uncertainties and 
 factors are described in detail under the caption "Risk Factors" and 
 elsewhere in our filings with the Securities and Exchange Commission, 
 including our Annual Report on Form 10-K for 2016 and our Quarterly 
 Report on Form 10-Q for the quarter ended March 31, 2017. Our filings 
 with the Securities and Exchange Commission are available in the 
 Investor Section of our website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glaukos.com&amp;esheet=51562780&amp;newsitemid=20170522005299&amp;lan=en-US&amp;anchor=www.glaukos.com&amp;index=3&amp;md5=7ae65c20cf5b8111babefb011093fabe" rel="nofollow" rel="nofollow">www.glaukos.com</a> 
 or at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51562780&amp;newsitemid=20170522005299&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=a8c9427067878441e086e2e7e44dcbb7" rel="nofollow" rel="nofollow">www.sec.gov</a>. 
 In addition, information about the risks and benefits of our products is 
 available on our website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glaukos.com&amp;esheet=51562780&amp;newsitemid=20170522005299&amp;lan=en-US&amp;anchor=www.glaukos.com&amp;index=5&amp;md5=2b4f98e53c076be73bd6abc6e0add931" rel="nofollow" rel="nofollow">www.glaukos.com</a>. 
 All forward-looking statements included in this press release are 
 expressly qualified in their entirety by the foregoing cautionary 
 statements. You are cautioned not to place undue reliance on the 
 forward-looking statements in this press release, which speak only as of 
 the date hereof. We do not undertake any obligation to update, amend or 
 clarify these forward-looking statements whether as a result of new 
 information, future events or otherwise, except as may be required under 
 applicable securities law.
 
 
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170522005299r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170522005299/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170522005299/en/</a></body></html>

Press Releases

Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent® Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma Patients - Glaukos (NYSE:GKOS)

Glaukos

GKOS

Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent® Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma Patients

RMBL


RumbleOn, Inc. (NASDAQ:RMBL) (the &#34;Company&#34; or &#34;RumbleOn&#34;), today announced that it will release its first quarter 2024 operational and financial results before the market opens on Wednesday, May 8, 2024.


The Company

RumbleOn Announces First Quarter 2024 Earnings Release and Conference Call Schedule

CSGP


CoStar Group, Inc. (NASDAQ:CSGP), a leading provider of online real estate marketplaces, information and analytics in the property markets, announced today that revenue for the quarter ended March 31, 2024 was $656

CoStar Group Successfully Launches Monetization of Homes.com in First Quarter 2024, with $39 Million of Net New Bookings Accelerating Overall Net New Bookings to a Record $86 Million

VREX


Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the second quarter of fiscal year 2024 following the close of regular trading on Thursday, May 2, 2024. The

Varex Schedules Second Quarter Fiscal Year 2024 Earnings Release and Conference Call

EWBC


East West Bancorp, Inc. (&#34;East West&#34; or the &#34;Company&#34;) (NASDAQ:EWBC), parent company of East West Bank, reported its financial results for the first quarter of 2024. First quarter 2024 net income was $285 million, or

East West Bancorp Reports Net Income for First Quarter of 2024 of $285 Million and Diluted Earnings Per Share of $2.03

FCOB


Income Statement Highlights include:



Net income was $1.6 million, for the first quarter of 2024, compared to net income of $1.5 million for the first quarter of 2023 and $2.1 million for the fourth quarter of

1st Colonial Bancorp, Inc. Reports First Quarter 2024 Net Income


AMCON Distributing Company (&#34;AMCON&#34;) (NYSE:DIT), an Omaha, Nebraska-based Convenience and Foodservice Distributor, is pleased to announce that the Board of Directors of AMCON declared a quarterly cash dividend of $0.18